We've found
15,024
archived clinical trials in
Infectious Disease
We've found
15,024
archived clinical trials in
Infectious Disease
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Click here to add this to my saved trials
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Click here to add this to my saved trials
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Click here to add this to my saved trials
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Click here to add this to my saved trials
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Click here to add this to my saved trials
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Click here to add this to my saved trials
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Click here to add this to my saved trials
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Click here to add this to my saved trials
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Click here to add this to my saved trials
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Click here to add this to my saved trials
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Click here to add this to my saved trials
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Click here to add this to my saved trials
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Click here to add this to my saved trials
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Click here to add this to my saved trials
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Click here to add this to my saved trials
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Click here to add this to my saved trials
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Click here to add this to my saved trials
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin
Updated: 10/21/2014
Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin
Status: Enrolling
Updated: 10/21/2014
Click here to add this to my saved trials
The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk
Updated: 10/21/2014
The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk
Status: Enrolling
Updated: 10/21/2014
The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk
Updated: 10/21/2014
The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk
Status: Enrolling
Updated: 10/21/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Updated: 11/5/2014
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Status: Enrolling
Updated: 11/5/2014
Click here to add this to my saved trials